Previous 10 | Next 10 |
4 Penny Stocks to Watch With June on the Horizon As we fast approach June, penny stocks are in highly volatile territory. This makes sense given the confusing and complicated times that we are living in. But, with so many penny stocks to watch right now, how can investors pick the b...
Sesen Bio, Inc. (SESN) Q1 2021 Results Earnings Conference Call May 10, 2021, 08:00 AM ET Company Participants Erin Clark - Vice President of Investor Relations Thomas Cannell - President and Chief Executive Officer Chad Myskiw - Strategic Planning, CMC Monica Forbes - Chief Financial Officer...
The following slide deck was published by Sesen Bio, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Sesen Bio, Inc. 2021 Q1 - Results - Earnings Call Presentation
Sesen Bio (SESN) shares fall more than 3% during premarket trading after the company posted a net loss in the first quarter of 2021.Net loss was $55.5M, or $0.35 per share, in the quarter, compared to net income of $41.6M, or $0.31 per share last year.General and administrative expe...
Sesen Bio (SESN): Q1 GAAP EPS of -$0.35 misses by $0.27.Cash, cash equivalents and restricted cash of $110M.Shares are down 1.12% PM.Press Release For further details see: Sesen Bio EPS misses by $0.27
Strengthened balance sheet with $110M in cash and cash equivalents as of March 31, 2021 Company remains on track for potential approval in the US in August 2021 and in Europe in early 2022 Company to host conference call at 8am ET Sesen Bio (Nasdaq: SES...
3 Penny Stocks For You May Watch List With the stock market ripping to record levels, traders continue seeking new opportunities. Penny stocks have become one of these niches identified for their uncapped potential. This year alone, there’ve been countless names that rally fr...
Sesen Bio is seeking an accelerated approval for its NMIBC therapy, Vicineum, and the PDUFA date is coming up soon on Aug. 18. Vicineum looks to fill a large need for additional pre-cystectomy therapies in patients who have already tried BCG therapy, and Sesen already inked two partne...
Company appoints experienced commercial leader, Lisa LaMond, to oversee sales strategy and execution Selected Syneos Health ® as partner for field sales execution in the US Company remains on track for potential approval in the US in August 2021 Se...
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company’s management team will host a conference call to review operating results for the first qua...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...